how-to
EU MDR Clinical Evaluation Report Requirements
Table of Contents
- What Is a Clinical Evaluation Report Under EU MDR
- Core Regulatory Requirements for EU MDR Clinical Evaluation Reports
- Developing a Clinical Evaluation Plan Template
- Clinical Evidence Requirements Under EU MDR
- Demonstrating Clinical Equivalence Under EU MDR
- CER Update Frequency and Post-Market Obligations
- Common Notified Body Audit Findings and How to Avoid Them
- Frequently Asked Questions
Last Updated: September 27, 2026
What Is a Clinical Evaluation Report Under EU MDR
A clinical evaluation report (CER) is a comprehensive document that demonstrates a medical device meets the clinical evaluation report requirements for clinical performance and safety mandated by the European Union Medical Device Regulation (MDR). Under EU MDR, manufacturers must provide clinical evidence showing their device is safe and performs as intended for its intended use.
Core Regulatory Requirements for EU MDR Clinical Evaluation Reports
The EU MDR imposes specific, non-negotiable clinical evaluation report requirements for clinical evaluation. These requirements flow directly from Article 61 and the General Safety and Performance Requirements (GSPR). Understanding these regulatory anchors is essential before you write a single page of your CER.
Article 61 and Conformity Assessment
Article 61 of the EU MDR establishes the legal foundation for clinical evaluation. It mandates that manufacturers conduct a clinical evaluation based on clinical data and, where appropriate, a systematic literature review. The Notified Body uses your CER to verify that your conformity assessment is complete and scientifically sound.
General Safety and Performance Requirements
The GSPR set the baseline clinical expectations for all medical devices under EU MDR. Your CER must explicitly map your clinical evidence to each applicable GSPR element. These include:
- Clinical performance of the device in its intended use
- Identification and analysis of known or foreseeable hazards
- Benefit-risk ratio assessment
- Post-market clinical follow-up data where required
- Comparison with state of the art alternatives
Developing a Clinical Evaluation Plan Template
Before you write your CER, you need a Clinical Evaluation Plan (CEP). The CEP outlines your strategy for gathering, analyzing, and presenting clinical evidence. It's your roadmap, and it must be documented before clinical data collection begins.
Key Sections of an Effective CEP
A strong CEP includes these core sections:
- Device description and intended use: Clear definition of what your device does and who uses it
- Clinical performance and safety objectives: Specific, measurable outcomes your device must achieve
- Clinical evidence strategy: How you'll gather data (clinical investigations, literature review, post-market data)
- State of the art analysis: How your device compares to existing alternatives
- Equivalence justification: If claiming equivalence, why your predicate device is appropriate
- Risk management integration: How clinical data addresses identified hazards
- Literature search strategy: Systematic approach to identifying relevant clinical evidence
- Post-market surveillance plan: How you'll monitor safety and performance after market release
Your CEP should be proportionate to your device's risk class and complexity. A Class I device may have a simpler CEP than a Class III implantable. The key is demonstrating that your approach is systematic and justified.
Timeline and Resource Allocation
Clinical evaluation isn't fast. Most manufacturers underestimate the time required for literature review, data analysis, and Notified Body interactions. A realistic timeline depends on your device class and evidence availability.
Common timeframes:
- Literature review and state of the art analysis: 4-8 weeks
- Clinical investigation planning and execution: 6-18 months (varies widely by device type)
- CER drafting and internal review: 3-6 weeks
- Notified Body review cycle: 2-4 months (often with requests for additional data)
Clinical Evidence Requirements Under EU MDR
Your CER must rest on solid clinical evidence. The EU MDR doesn't specify exact evidence types, but it requires that your evidence be sufficient, relevant, and scientifically valid. This means you need multiple evidence sources, not a single study.
Systematic Literature Review and State of the Art
A systematic literature review is mandatory for most device types. This isn't a casual search of a few databases. It's a structured, documented process where you search medical literature, identify relevant studies, appraise their quality, and synthesize findings.
Your literature review must address:
- What clinical evidence exists for your device type
- How your device performs compared to existing alternatives
- What safety issues are known in the field
- What clinical outcomes matter most to patients and clinicians
Notified Bodies scrutinize literature reviews intensively. They look for:
- Comprehensive search strategy with documented search terms
- Clear inclusion and exclusion criteria
- Quality assessment of included studies
- Transparent handling of conflicting evidence
- Honest discussion of limitations
Clinical Investigation Data and Scientific Validity
If published literature is insufficient, you'll need clinical investigation data. This means prospective studies with your device in real-world use. Clinical investigations require ethics approval, informed consent, and rigorous data management.
Your CER must document:
- Study design and rationale
- Patient population and selection criteria
- Primary and secondary endpoints
- Statistical analysis approach
- Results and interpretation
- Safety events and adverse reactions
Demonstrating Clinical Equivalence Under EU MDR
Many device manufacturers claim equivalence to predicate devices rather than generating entirely new clinical data. Equivalence is allowed under EU MDR, but it's heavily scrutinized. Your equivalence argument must be airtight.
Equivalence Criteria and Predicate Device Selection
Equivalence claims require that your device is as safe and effective as a predicate device already on the market. You must justify why your predicate is appropriate and why your device is truly equivalent.
Equivalence criteria typically include:
- Design equivalence: Same or similar materials, manufacturing process, and design features
- Performance equivalence: Same or similar performance characteristics and specifications
- Clinical equivalence: Same or similar clinical performance and safety profile
- Use equivalence: Same or similar intended use and patient population
Predicate device selection is critical. Your predicate must be:
- Legally marketed in the EU or another major market
- Appropriate for the same intended use
- Similar in design, materials, and performance
- Supported by adequate clinical evidence
Benefit-Risk Ratio Assessment
Your CER must present a formal benefit-risk assessment. This is where you weigh the clinical benefits of your device against known and potential risks.
Your benefit-risk assessment should include:
- Identified benefits: Therapeutic advantages, improved patient outcomes, reduced complications
- Identified risks: Known adverse events, potential complications, contraindications
- Risk mitigation: How design features, instructions, and training reduce identified risks
- Overall conclusion: Statement that benefits outweigh risks for the intended population
CER Update Frequency and Post-Market Obligations
Your CER isn't a one-time document. EU MDR requires ongoing clinical evaluation throughout the device's lifecycle. This means updating your CER as new clinical data emerges and as your understanding of safety and performance evolves.
Post-Market Clinical Follow-Up Requirements
Post-market clinical follow-up (PMCF) is a structured process where you continue to monitor your device's safety and performance after market release. Your CER must include a PMCF plan that describes:
- What safety and performance data you'll collect
- How long you'll collect data
- What endpoints you'll monitor
- How you'll analyze and report findings
- How findings will trigger CER updates or device modifications
Triggering Events for CER Revision
Your CER must be updated when significant new clinical evidence emerges or when your device changes. Triggering events include:
- New clinical investigation data showing different safety or performance
- Adverse event reports suggesting unexpected risks
- Published literature contradicting your original assessment
- Device design modifications affecting clinical performance
- Changes to intended use or patient population
- Regulatory actions against similar devices
- Post-market surveillance data revealing new patterns
Common Notified Body Audit Findings and How to Avoid Them
After years of reviewing CERs, Notified Bodies have identified consistent patterns in inadequate clinical evaluations. Understanding these common findings helps you avoid them.
The most frequent audit findings include:
- Incomplete literature review: Searches that miss relevant studies or fail to use systematic methodology
- Weak equivalence justification: Predicate devices that aren't truly equivalent or differences that aren't adequately addressed
- Insufficient clinical data: Evidence that's too limited or doesn't address all relevant safety and performance questions
- Poor benefit-risk analysis: Assessments that ignore known risks or overstate benefits without supporting data
- Missing GSPR mapping: Failure to explicitly address how clinical evidence supports GSPR compliance
- Inadequate state of the art analysis: Insufficient discussion of how your device compares to existing alternatives
- Vague or unsupported claims: Clinical performance statements without corresponding data or references
- Poor documentation: Insufficient detail about how evidence was selected, appraised, and synthesized
Frequently Asked Questions
What is the difference between a Clinical Evaluation Plan and a Clinical Evaluation Report?
A Clinical Evaluation Plan (CEP) is a prospective document that outlines how you will gather and appraise clinical evidence before you compile the Clinical Evaluation Report. The CEP describes your strategy for systematic literature review, clinical investigation design, and data analysis. The Clinical Evaluation Report (CER) is the final document submitted with your conformity assessment dossier, presenting the clinical evidence, appraisal, and conclusions. The CEP guides your evidence-gathering process; the CER documents what you found and how it meets EU MDR requirements.
How often must you update a Clinical Evaluation Report after market approval?
There is no fixed schedule for CER updates under EU MDR. Instead, updates are triggered by specific events: significant changes to the device design or intended use, new clinical safety or performance data from post-market surveillance, changes in the state of the art, or regulatory requests from Notified Bodies. Many manufacturers conduct periodic reviews (annually or biannually) to assess whether new evidence warrants CER revision. Post-Market Clinical Follow-Up data must be incorporated when it becomes available. Your risk management and post-market surveillance procedures should define the process for determining when CER updates are necessary.
What clinical evidence is required to demonstrate equivalence under EU MDR?
To demonstrate clinical equivalence, you must identify an appropriate predicate device and provide evidence that your device has comparable clinical performance and safety profile. Evidence includes a systematic literature review of clinical data for the predicate, a comparison of design and material characteristics, performance testing results, and clinical investigation data or published literature supporting your device's performance. You must address any differences between your device and the predicate and explain why those differences do not affect clinical performance. The benefit-risk ratio must be favorable and comparable to the predicate. Equivalence claims require scientific justification and must be reviewed by your Notified Body during conformity assessment.
What are the most common reasons Notified Bodies reject or request major revisions to Clinical Evaluation Reports?
Common audit findings include: insufficient or outdated systematic literature reviews that miss relevant clinical data; weak equivalence justifications with inadequate predicate device comparison; failure to address the state of the art or new clinical evidence; incomplete clinical investigation data or inadequate scientific validity assessment; poor appraisal methodology or bias in literature selection; lack of clear linkage between clinical evidence and General Safety and Performance Requirements; insufficient post-market clinical follow-up planning; and missing or unclear benefit-risk analysis. To avoid these, ensure your CEP is thorough and documented early, conduct rigorous literature searches with transparent inclusion/exclusion criteria, engage clinical and regulatory experts in appraisal, and maintain detailed traceability between evidence and regulatory requirements throughout the CER.